Avalo Therapeutics, Inc. (AVTX) NASDAQ

10.80

-0.75(-6.49%)

Updated at September 26 04:00PM

Currency In USD

Avalo Therapeutics, Inc.

Address

540 Gaither Road

Rockville, MD 20850

United States of America

Phone

410 522 8707

Sector

Healthcare

Industry

Biotechnology

Employees

23

First IPO Date

October 14, 2015

Key Executives

NameTitlePayYear Born
Dr. Garry A. Neil M.D.President, Chief Executive Officer & Director1.03M1954
Mr. Christopher Ryan Sullivan CPAChief Financial Officer & Head of Investor relations629,4001984
Dr. Mittie Doyle FACR, M.D.Chief Medical Officer678,1221965
Dr. Solomon H. Snyder M.D.Founder and Chairman of Scientific Advisory Board01939
Dr. Barbara S. Slusher Ph.D.Founder and Member of Scientific Advisory Board01965
Mr. Paul C. Varki J.D., M.P.HChief Legal Officer01973
Dr. Lisa Hegg Ph.D.Senior Vice President of Program Management, Business Development & Corporate Infrastructure0N/A
Ms. Colleen MatkowskiSenior Vice President of Global Regulatory Affairs & Quality Assurance0N/A
Ms. Jennifer RileyChief Strategy Officer01975
Dr. Dino C. Miano Ph.D.Senior Vice President of CMC & Technical Operations0N/A

Description

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.